Does Cinqair treat all types of asthma?

No, Cinqair (reslizumab) from Teva Pharmaceuticals is not for initial asthma treatment, for less severe asthma, or for use as a rescue therapy.

Cinqair was FDA-approved in March 2016, and is used in more severe asthma with elevated eosinophils (a type of white blood cell) that has not responded well to initial treatments. Cinqair is an anti-interleukin-5 (IL-5) used in adults 18 years and older as an add-on therapy for the maintenance treatment of severe asthma in adults not well-controlled on their current asthma medications.

In studies, patients receiving Cinqair had fewer asthma attacks, a longer time to first attack, and improvement in lung functions tests. Common side effects with Cinqair include anaphylaxis (a severe, possibly life-threatening allergy), cancer, and muscle pain.